Drugs / Muzastotug
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07363408 | Dec 2026 → Jul 2027 expected | colorectal carcinoma | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05584670 | Nov 2022 → Jan 2027 expected | cancer | Sanofi | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05405595 | Jun 2022 → Oct 2026 expected | — | Adagene Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04645069 | Mar 2021 → Jan 2024 | — | Adagene Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT04524871 | Nov 2020 → Jul 2027 expected | liver cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06846268 | Apr 2025 → Dec 2027 expected | colorectal cancer | National University Hospital, Singapore | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Muzastotug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07363408 ↗ |
| Known as | ADG126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06846268 ↗ |
| Action | Inhibit | “anti-CTLA-4” NCT05405595 ↗ |
| Modality | Monoclonal antibody | “fully human monoclonal antibody” NCT05405595 ↗ |
| Route | Intravenous | “ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).” NCT04524871 ↗ |